Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease | Semantic Scholar
Recommended clinical guideline for the management of Kawasaki disease... | Download Scientific Diagram
Treatment Options for Refractory Kawasaki Disease
New Tool Twice as Accurate at Predicting Antibody Resistance Among U.S. Children with Kawasaki Disease - Be part of the knowledge - ReachMD
IJMS | Free Full-Text | Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker
Kawasaki Dis Canada on X: "Approximately 10% to 20% of patients with Kawasaki disease develop recrudescent or persistent fever at least 36 hours after the end of their IVIG infusion and are
An Overview of Kawasaki Disease
Kawasaki Disease: An Update on Diagnosis and Treatment - ScienceDirect
![PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d8f3d0e9bcb78fb7089e50d6f77d0efc0737cd69/5-Figure1-1.png "PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar")
PDF] Treatment Options for Refractory Kawasaki Disease | Semantic Scholar
JCI - Immune response to intravenous immunoglobulin in patients with Kawasaki disease and MIS-C
IVIG Treatment for Kawasaki Disease | AmeriPharma™ Specialty
Kawasaki Kids on X: "Day 4 of Kawasaki Disease Awareness Month IVIG Treatment for Kawasaki Disease is the most widely used treatment to stop the fever and inflammation in the child's body.
Frontiers | A New Scoring System for Prediction of Intravenous Immunoglobulin Resistance of Kawasaki Disease in Infants Under 1-Year Old
Frontiers | Kawasaki Disease
Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin | Semantic Scholar
Clinical Practice Guidelines : Kawasaki disease
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
2021 ACR/VF Kawasaki Guidelines - Vasculitis Foundation
Figure 1 | Archives of Disease in Childhood
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study - The Lancet Child & Adolescent Health
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Various adjuncts to IVIg help treat coronary artery abnormalities in pediatric Kawasaki disease | MDedge Pediatrics
Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials - eBioMedicine
Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease | Journal of the American Heart Association
